Floatz logo

16 assets in Urethra Cancer

Therapeutic assets addressing Urethra Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Urethra Cancer
Jonsson Comprehensive Cancer CenterP2BB (64)
Cabozantinib
Urethra Cancer
National Cancer Institute (NCI)P2B (60)
Cis-Diamminedichloroplatinum Ii
Urethra Cancer
Jonsson Comprehensive Cancer CenterP1/2B (60)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Urethra Cancer
Emory UniversityP2B (60)
Nivolumab
Urethra Cancer
M.D. Anderson Cancer CenterP2B (60)
Pembrolizumab
Urethra Cancer
Emory UniversityP2B (60)
Ipilimumab
Urethra Cancer
M.D. Anderson Cancer CenterP2B (59)
Atezolizumab
Urethra Cancer
National Cancer Institute (NCI)P2B (57)
Apsolol
Urethra Cancer
Emory UniversityP2CCC (53)
Eribulin Monomethanesulfonate
Urethra Cancer
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Urethra Cancer
M.D. Anderson Cancer CenterP2CCC (53)
Tocilizumab
Urethra Cancer
M.D. Anderson Cancer CenterP2CCC (53)
Avelumab
Urethra Cancer
Emory UniversityP2CCC (48)
Docetaxel
Urethra Cancer
Jonsson Comprehensive Cancer CenterP1CC (43)
Etoposide
Urethra Cancer
Jonsson Comprehensive Cancer CenterP1CC (43)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Urethra Cancer
National Cancer Institute (NCI)P1CC (43)